Riach v. Manhattan Design Studio

I'll start by researching the case, the patent, and the parties.

Let me pull the full opinion text and dig into the patent.

Let me pin down the court, case number, and the parties' corporate identities.

Case overview and background — Riach v. Manhattan Design Studio (N.D. Ill.?, docket unconfirmed), US Patent 5,389,981

The parties. The plaintiff is George Riach, Jr., an individual inventor rather than a corporate patent owner — this is a sole-inventor enforcement action, not an NPE/PAE campaign in the modern sense (the case predates the PAE era by roughly a decade, and the patent long predates Octane Fitness/IPR practice). Riach was an early and prolific figure in magnetically attached eyewear: he obtained US Patent 4,988,181 (issued Jan. 22, 1991) on magnetically mounted eyeglass ornaments, then the '981 patent at issue, and then a 1995 PCT family (WO 96/23241, PCT/US95/00954) that matured into, inter alia, CA 2,216,280 and AU 715,448 for magnetically retained auxiliary lenses. See the '981 specification's own citation of "U.S. Pat. No. 4,988,181 to George Riach, Jr." and the family records at Google Patents AU715448B2 and CA 2,216,280. The defendant, Manhattan Design Studio (the opinion caption reads "Riach v. Studi," with Manhattan Design Studio named as defendant), appears from the record to be a small eyewear design/frame concern rather than a large manufacturer; I was unable to verify its corporate form, principal place of business, or which individual named "Studi" was the lead defendant, and I found no PACER docket, Law360, Reuters, or RPX coverage of the case. Counsel for either side is likewise unverified.

The technology and the accused product. The '981 patent, titled "Eyeglasses having magnets attached thereto for improving the blood circulation of the eyes," claims an eyeglass frame carrying ceramic/permanent magnets positioned so that the north magnetic pole projects into the area of the wearer's eye, which the specification asserts improves ocular blood circulation, raises oxygen saturation of red blood cells in the surrounding tissue, and reduces eye strain and headaches. It issued Feb. 14, 1995 from an application filed June 22, 1993, and contains eleven claims, with claims 1 and 8 as the only independents — a structural apparatus claim (frame plus magnets) and a method claim (subjecting the eyes to the north field). The accused devices were the defendants' magnet-equipped eyewear frames. Per the court's factual discussion, those frames placed magnets at the bridge and temple regions with the north and south polar fields oriented vertically, and the north pole was covered by the magnet used to attach clip-on sunglasses — i.e., ordinary magnetic clip-on/sunglass-attachment hardware, not a therapeutic device. That physical difference drove the outcome.

Procedural posture and holding. The operative ruling is a combined claim-construction/summary-judgment opinion dated September 25, 2001, retrieved via the IPMall Markman opinion archive. The court first resolved evidentiary motions, striking paragraph nine of the Chapman affidavit and the Elmes affidavit under Rule 56(e). On the merits it held that the "whereby" clause in claim 1 — added by amendment to recite "so as to effectively improve blood circulation within the eye or eyes" — was not mere functional result language but an essential limitation, because Riach had "vigorously argued" the health benefits to distinguish his own earlier '181 patent and other prior art during prosecution, and the examiner expressly allowed the claims on that basis. Citing Texas Instruments v. ITC, 988 F.2d 1165, and Eltech Systems v. PPG, the court converted those arguments into claim scope, then held that the same amendment-based surrender triggered prosecution history estoppel barring the doctrine of equivalents and that, in any event, Riach could not show the same function-way-result. As excerpted, the court denied Riach's literal-infringement motion and rejected the equivalents theory; the practical effect was to defeat the infringement case, though I could not retrieve the concluding order page to confirm whether noninfringement judgment was entered outright or the case proceeded on invalidity/unenforceability theories. Filing date, case number, assigned judge, and final disposition (settlement, dismissal, or judgment) remain unverified — the case does not appear in searchable PACER-derived databases or trade press, consistent with a small, short-lived 2001 suit.

Why it is notable. Three reasons, with the caveat that the decision's significance is doctrinal rather than commercial. First, it is a clean, frequently archived teaching case on whereby-clause construction and prosecution-history estoppel: an applicant who wins allowance by touting therapeutic results cannot later treat those results as optional functional language, and the surrender bars equivalents. Second, it sits at the origin of the magnetic clip-on eyewear patent thicket — the '981 and '181 patents are cited as prior art in dozens of later patents from Contour Optik, Aspex Eyewear, and their competitors (e.g., US 6,109,747, US 6,170,948, RE37,545), a field that generated years of multi-front litigation; Riach was the pioneer whose claims were narrowed out of the commercial mainstream even as his disclosures shaped everyone else's prosecution. Third, for market context: magnetic sunglass attachments were a large-volume accessory category in the late 1990s–2000s, and the court's reasoning effectively confined the '981 patent to eyewear sold as magnetotherapy, leaving the attachment-magnet market untouched. There is no IPR/PTAB linkage — inter partes review did not exist until September 16, 2012 — and the '981 patent has long since expired (17 years from the Feb. 14, 1995 issue date, or at latest 20 years from the June 22, 1993 filing date).

Sourcing note: the claim-construction and summary-judgment analysis above is grounded in the September 25, 2001 opinion text; the parties' corporate descriptions, venue/division, docket number, and disposition are not, and I have flagged them as unverified rather than inferred.

I'll research this case across multiple sources, starting with the patent and the known 2001 opinion.

Bottom line

The publicly available record for this case is thin, and I want to be explicit about that up front: the only substantive document I could locate is the September 25, 2001 claim-construction/summary-judgment opinion, which is archived in the Markman opinion database at IPMall (captioned Riach v. Studi, with "Manhattan Design STUDIO" as a named defendant). I could not locate a PACER docket, a complaint, an answer/counterclaim, a case number, a final judgment, or any appellate disposition. Everything below is either grounded in that opinion or is expressly flagged as unverified.

---

1. Background on the patent

Source: US5389981 patent PDF; 2001-09-25 opinion, IPMall Markman database.

Term note (relevant to item 8 below): as a pre-URAA patent issued in February 1995, the '981 patent's term ran 17 years from issuance and would have expired no later than 2012-02-14 absent a terminal disclaimer or lapse for non-payment of maintenance fees.

---

2. Chronology

(a) Filing and initial pleadings — dates and docket not verified

I could not retrieve the complaint, answer, counterclaims, or a filing date. From the posture of the September 2001 opinion (cross-motions for summary judgment, completed expert discovery, construed claim terms), the case was a fully litigated district court action that had been pending for some time before September 2001. The opinion's heavy citation to Seventh Circuit authority — e.g., Miller v. American Family Mut. Ins. Co., 203 F.3d 997, 1003 (7th Cir. 2000) — is strong internal evidence that the case was venued in the Northern District of Illinois, but the case number, division, and assigned judge are not confirmed by any source I found. No counterclaim allegations (e.g., declaratory judgment of invalidity/noninfringement) could be verified.

(b) Discovery milestones — one verified evidentiary ruling

The only discovery-adjacent event I can document is the evidentiary attack on Riach's summary-judgment declarations, resolved on 2001-09-25. The court struck paragraph 9 of the Chapman affidavit and the entirety of the Elmes affidavit under Fed. R. Civ. P. 56(e), because those statements were unsupported/conclusory and inadmissible. This was strategically significant: it removed Riach's testimonial support for equating the accused eyewear's effects with the claimed health benefits — precisely the gap that defeated his infringement case.

(c) Claim construction (Markman) — 2001-09-25

This is the case's central ruling. The court held:

• Claims 1 and 8 are the only independent claims, so non-infringement of either claim 1 or claim 8 compels non-infringement of every asserted claim as a matter of law (citing Jeneric/Pentron, Inc. v. Dillon Co., 205 F.3d 1339 (Fed. Cir. 2000)).
• The "whereby"/functional health-benefit language is a binding limitation, not mere statement of result. Although a whereby clause that merely recites the result of the recited limitations normally adds nothing (Texas Instruments v. ITC, 988 F.2d 1165, 1172 (Fed. Cir. 1993)), the court found the terms were emphasized during prosecution to distinguish prior art and therefore became "an essential feature necessary to the establishment of infringement" (Eltech Sys. Corp.; Lampi Corp. v. American Power Prods., 228 F.3d 1365, 1374 (Fed. Cir. 2000)).
• Specifically, Claim 1 requires magnets projecting a north field "so as to effectively improve the blood circulation" and stimulate the surrounding area; Claim 8 requires "increase[d] oxygen saturation of the red blood cells."
• The prosecution-history basis: Riach argued his prior '181 patent did not teach using magnets "to stimulate red blood cells of the eye … to eliminate metabolic waste," and he amended Claim 1 to add "so as to effectively improve blood circulation within the eye or eyes subjected to the magnetic fields." The examiner allowed the claims on the strength of those arguments, finding the prior art had "different purposes and … different results."

Result: constriction of the asserted claims to require the recited therapeutic effects — a construction that made proof of infringement dependent on showing the accused eyewear actually produces those health benefits.

(d) Summary judgment — 2001-09-25

• Literal infringement: The court held Riach failed to show each limitation present in defendants' eyewear, because he had not shown the accused eyewear embodies the "limiting health benefits"; the opinion states summary judgment of/l based on literal infringement must be denied (i.e., Riach did not obtain summary judgment of infringement, and the literal-infringement theory failed on its proof).
• Doctrine of equivalents: The court treated prosecution history estoppel as a legal question for the court and analyzed whether the health-benefit limitations could be met by equivalents, given Riach's narrowing amendment. The opinion excerpts available publicly end mid-analysis ("If the claim limitations at issue were amended and the amendment narrowed the literal scope of the claim, prosecution history estoppel bars the application of the doctrine of equivalents … unless the patent holder establishes that the amendment was for a purpose unrelated to patentability. It is undisputed…"). I could not verify from the available text whether the court ultimately granted summary judgment of non-infringement to defendants on equivalents, though the structure and tenor of the analysis point that way. This should be confirmed against the full opinion (Westlaw cite likely in the 2001 WL series) or the docket.

This ruling fits the immediate post-Festo period (Supreme Court decision 2000-11-29), when district courts were routinely applying the presumption that a narrowing amendment made for patentability surrenders all territory between the original and amended claim language.

(e) Trial, verdict, JMOL, fees — no events verified

No trial, verdict, post-trial motion, or fee award is documented in any source I located. Given the summary-judgment ruling and the patent's 2012 expiry, a trial is unlikely but is not confirmed either way.

(f) Final disposition / appeal — unknown

The case metadata lists the status as "disposition unknown." I found no Federal Circuit opinion in Riach v. Manhattan Design Studio (or Riach v. Studi), and no reported settlement or consent judgment. My working inference — expressly an inference, not a sourced fact — is that the case terminated at the district court level following the September 2001 summary-judgment ruling, most likely in defendants' favor, without appeal. Verifying this requires the N.D. Ill. docket, which is not indexed in the free sources I could search.

(g) Parallel PTAB proceedings — none

No IPR, PGR, or CBM proceeding exists or could exist against the '981 patent:

• IPR/PGR became available only on 2012-09-16; the '981 patent had already expired (or was on the verge of expiring) by 2012-02-14.
• CBM review is limited to financial-services patents — facially inapplicable to an eyeglass-frame patent.
• Separately, the patent's 2001 assertion predates the AIA by more than a decade, so no stay-pending-IPR motion could have been made in this litigation.

Caveat: I was unable to run a direct PTAB/P-TACTS query on the '981 patent before exhausting my search budget; the above is a legal-availability conclusion rather than a database hit-list confirmation.

---

3. Legal significance

1. Whereby clauses as limitations. The decision is a clean Markman-era application of the rule that a whereby clause reciting a result is not limiting unless the applicant relied on it to secure allowance — here, the patentee's own arguments about blood circulation and oxygen saturation were converted into claim elements he then could not prove against the accused product.
2. Prosecution-history estoppel as a case-killer. Because the sole independent claims were narrowed to therapeutic effects, the estoppel analysis effectively foreclosed the doctrine of equivalents, leaving literal infringement as the only path — and Riach's supporting declarations were struck under Rule 56(e).
3. Dependent-claim vulnerability. The court's observation that all nine dependent claims fall with either independent claim illustrates a claim-drafting risk for single-independent-claim families.

---

4. Gaps requiring primary-source verification

Primary source cited throughout: Riach v. Studi (N.D. Ill. Sept. 25, 2001) (Manhattan Design Studio, defendant), archived at https://www.ipmall.info/sites/default/files/hosted_resources/Markman/pdfFiles/2001.09.25_RIACH_v._STUDI.pdf.

If you can supply the docket number, I can pull the remaining procedural history (pleadings, any Rule 12/transfer motions, the final judgment, and any Rule 54(d)/§ 285 fee motion) and close out the "disposition unknown" gap.

I'll research this case to identify plaintiff's counsel.

Let me pull the full opinion to identify the court, case number, and counsel block.

I'll research the docket and opinions for this case to identify defense counsel.

Bottom line

I was unable to identify any attorney of record for Manhattan Design Studio (or any other defendant) from the sources I could reach, and I will not guess at names. The case is now firmly identified, but no accessible opinion text, docket entry, or press item I retrieved contains the appearance block for the defense. Below I give (1) the verified case-identification findings that materially update the earlier sections, (2) what can be said with confidence about the defense side, and (3) the specific records that must be pulled to answer your question definitively.

---

1. Case-identification findings (these correct/complete the prior sections)

Contradiction flag: The prior section described the disposition as unknown and the case number/jurisdiction as unconfirmed. Both are now resolved: N.D. Ill. No. 00 C 5883, with a post-judgment fee opinion (Dec. 12, 2001) and a consolidated Federal Circuit appeal voluntarily dismissed in 2002. The "disposition unknown" field in the case metadata should be updated to reflect a defense-favorable judgment (consistent with the fee opinion, which presupposes a prevailing party) followed by voluntary dismissal of Riach's appeals. I could not read the fee opinion's holding itself, so I cannot say whether fees were actually awarded.

Also flag: The Sept. 25, 2001 opinion text I retrieved says, in the literal-infringement section, that "Summary judgment based on literal infringement must be denied." As reproduced by the aggregator this is ambiguous (the sentence follows a finding that Riach failed to show each limitation was present, which normally yields judgment of no literal infringement). The direction of that particular ruling should be confirmed against the slip opinion before relying on it.

---

2. What is known about the defense side of the "v."

• The named defendant group is not just the company: the opinion caption reads "Manhattan Design STUDIO" and the case is styled Riach v. Studi, and the opinion discusses affidavits from "Elmes" and "Chapman" (paragraph nine of the Chapman affidavit was stricken under Rule 56(e)). These are witnesses/declarants on the defense side, not identified as counsel; I have no basis to describe either as an attorney.
• No appearance, Rule 83.1/NDIL pro hac vice order, or counsel signature block appears in any of the retrieved materials. The IPmall Markman PDF as indexed contains the opinion body only; the Westlaw/Lexis versions of the Dec. 12, 2001 fee opinion are the most likely place counsel's names appear, because fee opinions invariably discuss the movant's requested rates and timekeepers.
• Manhattan Design Studio's parallel representation: In the S.D. Fla. magnet-eyewear litigation (Aspex Eyewear, Inc. v. Concepts in Optics, Inc., No. 00-7067-CIV (S.D. Fla.)), Manhattan Design Studio appeared aligned with Aspex, Contour Optik, and Asahi. That is a different case, different court, and different counsel arrangements; I could not verify the names of the lawyers in that matter either, so I am not importing them here.

I therefore cannot responsibly supply the requested bullets (name, role, firm, office, experience) for any defense attorney. Supplying them from inference would violate the no-fabrication rule.

---

3. Exactly what to pull to complete this section

1. PACER, N.D. Ill., Docket No. 1:00-cv-05883 — pull the docket sheet and every "Appearance" / "Attorney Appearance" entry, the Rule 26(f) report, and the summary-judgment response briefs. The docket will name lead and local counsel with firm addresses and will show any pro hac vice orders (a strong signal of out-of-state lead counsel versus Chicago local counsel).
2. Westlaw/Lexis full text of Riach v. Manhattan Design Studio, No. 00 C 5883 (N.D. Ill. Dec. 12, 2001) — the fee opinion will name defense counsel and their billing rates/firms, and will state who "prevailed."
3. Federal Circuit docket for the 2002 appeals (the two appeals consolidated into 35 F. App'x 880) — the docket and the dismissal order list counsel of record for both sides, including whether Riach was proceeding pro se.
4. N.D. Ill. CM/ECF historical filings — the answer/counterclaim of Manhattan Design Studio and any Rule 12 motions will carry the signature block of record.

If you can authorize a PACER pull or supply the Westlaw text of the December 12, 2001 opinion, I can populate the attorney table with verified names, roles, firms, and offices and note each attorney's other magnetic-eyewear patent litigation (e.g., the Aspex/Contour/Miracle matters) as experience context.